ACTA1 and supranuclear palsy, progressive, 1: In the current study, the α-SMA-positive area was significantly larger in group PSP than in group H, indicating that PSP treatment may reduce HFD-related pathological changes in MECs and may serve to ameliorate the effects of DED.